An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

news-events

Satya’s MedChem leadership expanded

Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery programs in Oncology, Metabolic Disorders, and CNS therapeutic areas. Navnath previously worked at Dai-Ichi and Lupin, after his PhD from Pune University and post-doc from Rouen, France. Ganesh Gudade, with over 20 years of MedChem experience at Lupin, Glenmark and …

Satya’s MedChem leadership expanded Read More »

Satya expands lab infrastructure

Satya is expanding its lab infrastructure and team size at its facilities in Hyderabad, India to add additional discovery programs to the pipeline. Upon completion, the lab size would double and the company can run up to six discovery programs in parallel.

Satya presents 2 e-posters at the AACR Annual Meeting

Poster 6368: “Discovery of potent, orally bioavailable, SOS1 inhibitors for KRAS-driven tumors” Abstract   KRAS is an oncogene implicated in a wide variety of tumors (~21% of solid tumors harbor KRAS mutations). KRAS interaction with Guanidine Exchange Factors (GEFs) is crucial for its activation, with SOS1 being the predominant GEF. SOS1 inhibition is thus expected …

Satya presents 2 e-posters at the AACR Annual Meeting Read More »

Satya presents poster on its RAD51-BRCA2 disruptor program at AACR, New Orleans April 8-13

Poster #LBA041: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer, October 7-10, 2021 The DNA damage response (DDR) is a complex cellular network that acts as a cell defense mechanism and exerts signal for repair of DNA lesions. It repairs different types of DNA damage such as single-strand (ssDNA) breaks, DNA inter-strand crosslinks and …

Satya presents poster on its RAD51-BRCA2 disruptor program at AACR, New Orleans April 8-13 Read More »

Scroll to Top